Awaiting development: Guidance and quality standards

Showing 41 to 50 of 87

Guidance and quality standards awaiting development
Title	Type
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [TSID12395]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]	Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]	Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance